Items Tagged with 'Pfizer Inc. (NYSE: PFE)'
PFE Complete $11.85 billion Sale
November 30, 2012
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
PFE Announces Revenues of $14.0 billion
November 1, 2012
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion
July 31, 2012
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
PFE Obtains FDA Approval for Lyrica
June 21, 2012
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
PFE Reports 7% Revenue Decrease
May 1, 2012
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
Pfizer Buys Vitamin C Icon
February 27, 2012
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
February 1, 2012
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
January 27, 2012
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
January 17, 2012
On January 17, 2012, Medivation, Inc.(NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.
December 30, 2011
On December 30, 2011, Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.
Profit from The Turnaround Letter's...
Market-Beating Investment Results
27+ Years of Turnaround Experience
Diverse Stock Picks for Today's Unpredictable Market
Distressed Investing Blog
The S&P 500 has been one of the best stock market performers recently but that does not mean that all of its component stocks have fared well. We’ve identified select bottom performers with significant turnaround potential for those contrarians willing to bet against the crowd.
Free Stock Report
Put George Putnam's 27+ years of market-beating, contrarian investing advice to work for you, and give your portfolio a boost with this FREE stock report.
Current Total Returns
Total returns cover the fulll year 2013.
Note: Returns are not adjusted for inflation.
Copyright © 2014 All Rights Reserved for TurnaroundLetter.com Site Content. New Generation Research, Inc.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.